Need to keep on high of the science and politics driving biotech as we speak? Join to get our biotech e-newsletter in your inbox.
Good morning, and joyful birthday to me! As we speak, we see the Senate Appropriations Committee look to extend NIH funding, regardless of the Trump administration’s request to slash it. Additionally, Trump makes drug pricing calls for, and extra.
The necessity-to-know this morning
- Regeneron Prescribed drugs mentioned the FDA rejected odronextamab, a therapy for follicular lymphoma. The company may also delay selections on two purposes looking for expanded use of its eye drug Elyea. All three purposes have been negatively impacted by points discovered by FDA inspectors at a Catalent contract manufacturing facility, Regeneron mentioned. The Catalent facility was just lately acquired by Novo Nordisk.
- Moderna and Regeneron reported second-quarter earnings.
Trump calls for drugmakers slash U.S. value now
President Trump yesterday intensified his push to pressure pharmaceutical firms to align U.S. drug costs with these in different rich nations, sending letters to 17 main firms and demanding compliance by Sept. 29. The letters name for sweeping adjustments, STAT’s Elaine Chen writes, together with providing Medicaid and Medicare medication at costs akin to the bottom ranges in international locations a part of the Group for Financial Co-operation and Improvement which have at the very least 60% of the U.S. GDP. The letter additionally referred to as to broaden direct-to-consumer gross sales of high-rebate medication, and repatriating overseas earnings.
